Prostigmine

Quick links to important sections

Prostigmine

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prostigmine

Quick Facts

Property Description
Active ingredient Neostigmine
Pharmacological class Cholinesterase Inhibitor
Origin Synthetic Compound
Primary Forms Solution for Injection and Oral Tablet
General Purpose Enhances nerve-to-muscle signaling

What Type of Medicine is Prostigmine (Neostigmine)?

Prostigmine is a commercially recognized product containing the active ingredient Neostigmine. Pharmacologically, Neostigmine is classified as a synthetic, indirect-acting cholinesterase inhibitor, a class of agents clinically recognized for their ability to modify synaptic transmission. This single-ingredient compound is chemically distinguished by its quaternary ammonium group, a feature that prevents it from readily crossing the blood-brain barrier, thereby restricting its effects mainly to the peripheral nervous system.

This focused peripheral action is a differentiating factor, contrasting it with other cholinergic agents that may have more significant central nervous system effects. Neostigmine is available in two salt forms: Neostigmine bromide for the oral tablet formulation and Neostigmine methylsulfate for the sterile solution for injection. The general purpose of Neostigmine is to help restore or augment function where signal transmission to muscles or certain organs is weakened or compromised.

How Does Neostigmine Function and What Forms Are Available?

Neostigmine functions by causing a temporary and reversible inhibition of the acetylcholinesterase enzyme, which is naturally tasked with rapidly breaking down the neurotransmitter acetylcholine. Through its affinity for the enzyme active site, Neostigmine prevents this degradation, increasing and prolonging the concentration of acetylcholine at the nerve connections and effectively strengthening the nerve-to-muscle signal.

This augmented cholinergic transmission provides the general therapeutic benefit of facilitating stronger and more sustained muscle contraction, typically relevant in scenarios of weakened neuromuscular activity. Its general purpose is therefore to help improve skeletal muscle strength and restore or increase the movement (motility) of smooth muscles—for instance, in the digestive tract. The availability of both the oral and injectable forms allows for administration tailored to the patient’s need for either a sustained systemic effect or a more immediate response.

Regulatory References

  1. Neostigmine - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Prostigmine?

Prostigmine (neostigmine) is a medication that primarily affects the cholinergic system, which can result in a wide range of side effects related to overstimulation of various nerve receptors.

Common and Serious Adverse Reactions

The most commonly reported adverse effects are bradycardia (slowed heart rate), nausea, and vomiting.

Serious and potentially life-threatening reactions that have been documented include cardiac arrest, respiratory arrest, and severe allergic reactions such as anaphylaxis. Other serious cardiovascular effects include cardiac arrhythmias and hypotension (low blood pressure).

Warning: Cholinergic Crisis

Overdosage of Prostigmine can lead to a condition called cholinergic crisis, characterized by increasing muscle weakness that can progress to respiratory paralysis and death. It is medically crucial to distinguish this from a myasthenic crisis, as both conditions cause extreme muscle weakness but require different management.

Contraindications and Precautions

Prostigmine is contraindicated in patients with a known hypersensitivity to the drug, or in the presence of peritonitis or mechanical obstruction of the intestinal or urinary tract.

Caution is advised when the drug is used in individuals with pre-existing conditions such as bronchial asthma, cardiac arrhythmias, coronary artery disease, bradycardia, epilepsy, or peptic ulcer. The risk of heart rate and blood pressure complications is increased in patients with certain cardiovascular conditions.

For obstetric use, anticholinesterase drugs, including neostigmine, have been reported to cause uterine irritability and potentially induce premature labor when administered intravenously to pregnant women near term.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Prostigmine (Neostigmine) results in a severe, potentially life-threatening syndrome known as Cholinergic Crisis, which necessitates immediate medical intervention.

Documented Manifestations and Severe Outcomes

Official regulatory documents identify this crisis by a documented cluster of symptoms affecting multiple systems. Manifestations include severe muscarinic effects such as excessive salivation, vomiting, diarrhea, and miosis (pinpoint pupils). Nicotinic effects involve generalized muscle weakness, muscle cramps, and fasciculations (muscle twitches). The most severe, life-threatening outcomes documented are respiratory failure leading to respiratory arrest, and cardiac arrest, often preceded by profound bradycardia (slowed heart rate) or hypotension.

Required Emergency Actions

Urgent medical attention must be sought immediately when severe symptoms, particularly difficulty breathing, are suspected. The primary regulatory mandate is the immediate discontinuation of all cholinergic medication. Maintenance of adequate respiration is stated as being of primary importance, potentially requiring assisted or mechanical ventilation.

Antidote and Management

Atropine Sulfate is the specific agent administered intravenously to control the muscarinic symptoms of overdosage. However, it is officially noted that Atropine does not reverse the critical nicotinic effects (muscle weakness/paralysis), necessitating comprehensive supportive measures. In Myasthenia Gravis patients, the major symptom may be increased muscular weakness, making differentiation from a Myasthenic Crisis clinically difficult.

Therapeutic Uses of Prostigmine

Main Therapeutic Uses

Prostigmine, known generically as neostigmine, is a medication primarily used to improve muscle strength and facilitate communication between nerves and muscles. It belongs to a class of drugs called cholinesterase inhibitors.

Myasthenia Gravis

The most common application of Prostigmine is the management of myasthenia gravis. This is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles, which are responsible for breathing and moving parts of the body, including the arms and legs. The medication helps by preventing the breakdown of acetylcholine, a naturally occurring substance in the body that is essential for muscle contraction.

Reversal of Neuromuscular Blockade

In hospital settings, Prostigmine is frequently utilized after surgical procedures. During surgery, certain medications are often administered to induce muscle relaxation or paralysis. Prostigmine is used to reverse the effects of these non-depolarizing muscle relaxants, helping patients regain muscle control and resume spontaneous breathing as they recover from anesthesia.

Postoperative Conditions

Prostigmine is sometimes employed to treat specific functional issues that occur following surgery, such as:

  • Urinary Retention: It can help stimulate the bladder muscles to facilitate urination when a patient is unable to empty their bladder naturally after an operation.
  • Paralytic Ileus: It may be used to stimulate movement in the intestines if they have become inactive or "sluggish" following abdominal surgery, helping to move gas and contents through the digestive tract.

Benefits and Expected Outcomes

The primary benefit of Prostigmine is the restoration or enhancement of muscle function. For individuals with chronic conditions like myasthenia gravis, the medication can significantly improve daily quality of life by reducing muscle fatigue and increasing physical endurance. In acute surgical settings, it serves as a critical tool for safely transitioning patients from a state of induced muscle relaxation to independent physical function.

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

The eligibility profile for Prostigmine (neostigmine) is defined by strict regulatory criteria, specifying populations who are prohibited from using the medicine and those who require conditional use or special monitoring.

Classification Official Regulatory Status
Populations Contraindicated Patients with known hypersensitivity to neostigmine or its salts, or those with mechanical obstruction of the intestinal or urinary tracts, or peritonitis.
Age-Group Eligibility Adults and Pediatric Patients (including neonates) are eligible for approved uses; however, older adults require extended monitoring due to the potential for prolonged drug effect from reduced renal function.
Organ Function Restrictions Use requires close monitoring in patients with renal impairment due to the drug's prolonged elimination half-life. Caution is advised in the presence of hepatic impairment.
Conditional Use Caution is mandatory for individuals with underlying conditions such as coronary artery disease, cardiac arrhythmias, recent acute coronary syndrome, bronchial asthma, or peptic ulcer disease.
Reproductive Status Use in pregnant women is permitted only if clearly needed, as adequate human studies are lacking and the drug may induce premature labor near term. Caution is required for nursing mothers.

Connection to the Overall Eligibility Profile

Regulatory documents establish clear non-eligibility for patients with internal mechanical blockages. The eligibility is otherwise conditional, requiring a formal assessment in patients with specific heart or lung conditions. The drug is allowed across all age groups for certain indications, but only under the condition of strict monitoring in vulnerable populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Neostigmine (Prostigmine) is defined by pharmacodynamic interactions that affect neuromuscular function and autonomic control, as documented in official prescribing information.

Documented Interaction Constraints

Constraint Type Interacting Agent / Class
Formal Contraindication Depolarizing Muscle Relaxants (e.g., Succinylcholine)
Mandatory Timing Rule Anticholinergic Agents (e.g., Atropine, Glycopyrrolate)
Use-with-Caution Other Cholinesterase Inhibitors, Antiarrhythmic Agents, Aminoglycoside Antibiotics

Co-administration with depolarizing muscle relaxants is prohibited for the reversal of neuromuscular blockade, as Neostigmine may prolong the Phase I block. Conversely, Neostigmine's therapeutic use is the effective antagonism of non-depolarizing neuromuscular blocking agents.

To manage Neostigmine’s muscarinic effects, anticholinergic agents must be administered prior to or concomitantly with the Neostigmine injection. The co-use of other cholinesterase inhibitors or beta-blockers may result in additive adverse cholinergic or bradycardic effects, respectively. Additionally, official documents note that the drug’s clearance may be affected in patients with impaired hepatic or renal function, potentially leading to increased drug exposure.

Mechanism of Action

Prostigmine, which is neostigmine bromide, functions as a reversible acetylcholinesterase inhibitor (AChEI).

Neostigmine targets the acetylcholinesterase (AChE) enzyme located in the synaptic clefts, primarily at the neuromuscular junction (NMJ). It interacts with the enzyme's esteratic site, forming a carbamoylated enzyme intermediate. This reversible carbamoylation transiently inactivates AChE, preventing the rapid hydrolysis of the neurotransmitter acetylcholine (ACh) into choline and acetate. This interaction is classified as non-competitive or mixed-type inhibition based on precise binding kinetics, but its primary consequence is to reduce the enzyme's catalytic efficiency.

The molecular inhibition of AChE leads to an increase in the local concentration of ACh within the synaptic cleft. This elevated ACh concentration enhances the activation of postsynaptic nicotinic acetylcholine receptors (nAChRs) on skeletal muscle cells and muscarinic acetylcholine receptors (mAChRs) throughout the parasympathetic nervous system. At the NMJ, the prolonged and intensified ACh binding to nAChRs increases the probability of achieving a threshold potential, leading to enhanced muscle fiber depolarization. This increased cholinergic signaling results in modulation of skeletal muscle contractility and potentiation of parasympathetic tone in affected tissues, which represents the system-level physiological consequence.

Dosage and Administration Information

Administration Routes and Forms

Prostigmine is administered through distinct routes, depending on whether chronic management or an immediate, acute effect is required. The oral tablet containing neostigmine bromide is designated for long-term use, while the sterile solution, containing neostigmine methylsulfate, is administered parenterally via the intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes. IV injection must be performed slowly, over a minimum of one minute.

Official Dosing Regimens

Specific dosage ranges are defined for each approved clinical context. Dosing may require adjustment based on the patient's renal function, as the medication is primarily excreted by the kidneys.

Indication Administration Route Typical Adult Dosing Range
Myasthenia Gravis (Maintenance) Oral 15 mg to 30 mg initial dose; up to 375 mg total daily dose, divided.
Neuromuscular Blockade Reversal Intravenous (IV) 0.03 mg/kg to 0.07 mg/kg, not to exceed 5 mg total.

For chronic oral management of Myasthenia Gravis, the total daily dose is divided and taken multiple times throughout the day. Intake is often scheduled for 30 to 60 minutes before meals to provide maximal muscle function during eating. The use of neostigmine for neuromuscular blockade reversal is a procedural requirement in a supervised setting, and it must be administered concomitantly with or immediately prior to an anticholinergic agent.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Prostigmine

This overview summarizes the type of research that has been conducted on Prostigmine (neostigmine). This information is provided to help contextualize the evidence landscape and should not be used as a substitute for professional medical advice.


Evidence for Symptomatic Control of Myasthenia Gravis

Research exploring the use of Prostigmine for managing the symptoms of Myasthenia Gravis (MG) largely includes older observational cohorts, retrospective studies, and pharmacological reports. In these contexts, Prostigmine was studied for its impact on outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level.

Studies research examined different methods used in clinical settings to measure symptom change over time. Studies contribute to the broader evidence landscape for this condition, which is characterized by fluctuating or episodic manifestations. Data for chronic, long-term use are often based on observational data rather than large, contemporary randomized, controlled trials (RCTs).


Evidence for Reversal of Non-Depolarizing Neuromuscular Blockade

A substantial body of research, including Randomized Controlled Trials (RCTs) and systematic reviews, was evaluated in the context of the operating room and immediate post-surgical recovery. Prostigmine was studied for its role in recovery, with researchers precisely measuring the time to recovery of critical muscle function parameters. Studies also monitored acute physiological changes during defined time intervals. Research examined short-term changes and acute recovery times, but the long-term effects are not fully established.


Evidence in Special Populations and Subgroups

Research was evaluated in various patient groups where the evidence structure appears to differ from the general adult population. For example, studies explored its use in older adults. Limited research was observed in pediatric patients with Myasthenia Gravis. Data on patients who have specific comorbidities or concurrent health issues are limited. Similarly, research describes limited data for populations involved in pregnancy-related use; findings in these specific groups are uncertain. Therefore, results apply only to the populations studied in the existing trials.


What is Still Uncertain About Prostigmine Research

Evidence is limited for long-term outcomes, especially regarding the effect on the chronic progression of Myasthenia Gravis. Evidence regarding alternative approaches remains limited in modern trials. Subgroup findings are uncertain for specific, less-studied patient populations. The structural differences in study design mean that evidence quality varies across studies, and findings were mixed or inconsistent across the full range of outcomes monitored. Research provides context but not individual predictions about how any single person will respond.

Key Studies & References

  1. Management of Myasthenia Gravis: Clinical Practice Guideline
  2. Neostigmine versus sugammadex for reversal of neuromuscular blockade: a systematic review and meta-analysis of randomized controlled trials

Frequently Asked Questions (FAQ)

Common questions about Prostigmine (FAQ)

Q: What are the main approved uses of Prostigmine?

Official regulatory documents indicate that Prostigmine is used for two main purposes. It is prescribed to manage the symptoms of myasthenia gravis, a condition causing muscle weakness. Additionally, it is used in a supervised setting to help reverse the effects of certain muscle relaxants following surgical procedures.

Q: Is Prostigmine used for purposes other than muscle weakness?

Yes, certain formulations of the active ingredient, neostigmine, have approved uses beyond muscle weakness disorders. Official product information describes its use for specific cases of smooth muscle issues, such as post-operative urinary retention or intestinal distension where no physical blockage is present.

Q: Why is the injection form of Prostigmine used in hospital settings?

The injection form of Prostigmine is reserved for medical procedures because it is designed to achieve an immediate, acute effect. It is most commonly administered in a supervised hospital setting to quickly reverse the effects of non-depolarizing muscle relaxants used during surgery.

Q: Can Prostigmine cause stomach problems like nausea or diarrhea?

Yes, common gastrointestinal effects are associated with Prostigmine because of its action on the nervous system. These documented adverse reactions include nausea, vomiting, abdominal cramps, and diarrhea.

Q: What should I know about taking Prostigmine for a long period of time?

For chronic, long-term management, regulatory information indicates that monitoring may be required, especially if there are existing kidney or liver conditions. This caution is advised because the medication is primarily cleared from the body by the kidneys, and impairment could lead to a prolonged drug effect.

Q: What are the general expectations when starting treatment with Prostigmine?

As Prostigmine works on the cholinergic system, regulatory documents describe that certain effects may be experienced when starting treatment. These documented effects include a slow heart rate (bradycardia), increased salivation or sweating, and gastrointestinal symptoms like nausea, vomiting, or muscle twitches.

Q: What are the general reasons why a patient might discontinue use of Prostigmine, as mentioned in clinical literature?

Official safety documentation describes that the medicine is not appropriate for use if certain conditions are present, such as a mechanical obstruction in the intestines. Discontinuation during treatment may be required if severe adverse effects develop, including cardiovascular complications or signs of cholinergic crisis (extreme muscle weakness).

Q: What medical specialists typically prescribe or administer Prostigmine?

The prescribing and administration of Prostigmine are handled by specialists appropriate to the specific condition being managed. For chronic conditions like myasthenia gravis, neurologists typically prescribe it, while anesthesiologists commonly administer the injectable form in the operating room for post-operative recovery.

Q: What are the possible signs of an allergic reaction to Prostigmine?

Documented signs of a serious hypersensitivity reaction, which is an extreme allergic response, include rash and itching. More severe indicators may involve swelling of the face, tongue, or throat, or the presence of severe dizziness and difficulty breathing.

Q: Is it normal to experience increased sweating or salivation with Prostigmine?

Yes, increased sweating and increased salivation are known side effects, as documented in the official adverse event profile. These effects are a manifestation of the drug’s action on the nervous system, which stimulates glands involved in these bodily functions.

Q: Can Prostigmine affect sleep or cause fatigue?

The adverse event profile includes reports of effects that may relate to sleep patterns. Both sleeplessness (insomnia) and, conversely, drowsiness have been reported in association with the use of the medicine, though the frequency of these events is not always known.

Q: Does Prostigmine interact with common over-the-counter pain relievers?

Regulatory information notes that potential interactions exist between Prostigmine and certain drugs commonly used for pain relief. These documented interactions include substances like acetaminophen and aspirin.

Q: How long does it take for Prostigmine to start working after it is taken?

The timing of the medicine's onset depends on the administration route. For the injectable form, the peak effect is typically achieved within 10 to 30 minutes. The onset of effect for the oral tablet formulation, which is used for chronic conditions, is generally slower than the injection.

Q: How long does the therapeutic effect of one dose of Prostigmine last?

The duration of the therapeutic effect for a single dose of neostigmine typically lasts for up to four hours. After this time, the active ingredient is primarily excreted from the body via the kidneys.

Q: Is Prostigmine considered a controlled substance?

Official regulatory scheduling indicates that Prostigmine (neostigmine) is not classified as a controlled substance under the U.S. Controlled Substances Act (DEA scheduling).

Q: Can Prostigmine cause dry mouth or changes in vision?

Yes, the official adverse event profile documents potential effects on the eyes and mouth. These documented adverse reactions include dry mouth, blurred vision, or other changes in vision.

Q: Is Prostigmine available as a generic medicine?

Yes, Prostigmine is a brand name for the active ingredient neostigmine. This active ingredient is available in both generic formulations and under various brand names.

How should Prostigmine be stored and disposed of?

How to Store and Dispose of Prostigmine (Neostigmine)

The storage and disposal of Prostigmine must adhere strictly to officially documented regulatory requirements to maintain product stability and ensure safety.


Storage Conditions

Prostigmine for injection must be stored at controlled room temperature, specifically maintained between 20 C and 25 C. The product is required to be protected from light and must not be frozen at any time. If stored in the oral tablet form, the container must be kept tightly closed.


Safety and Disposal

All forms of Prostigmine must be stored out of the sight and reach of children. Unused or expired medication should not be disposed of by flushing it down a toilet or pouring it down a drain. Instead, disposal must follow local guidelines, typically through a formal medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prostigmine found in:

A-Z Index: